Zydus Cadila has received the final approval from the USFDA to market Glyburide and Metformin Hcl Tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg.
[adsense:336x280:8701650588]
The drug falls in the anti - diabetics segment and the group’s formulations manufacturing site at Baddi will be producing the drug for the US market.
[adsense:468x15:2204050025]
The group now has 103 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003 - 04.
